Company profile
Amylyx Pharmaceuticals, Inc.
NASDAQ: AMLX · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
51DFH 68DQ 48GM 2SS 56
v0.1 · 65/100 weight · provisional
↑ Altman-Z, balance-sheet leverage · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$144.7M
Employees
136
as of 2026-08-09
Market cap
$2.5B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$144.7M-$144.7M2025
Operating income-$153.3M-$153.3M2025
Total assets$332.6M$332.6M2025
Liabilities$27.4M$27.4M2025
Equity$305.3M$305.3M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Amylyx Pharmaceuticals, Inc.’s revenue?
Amylyx Pharmaceuticals, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Scholar Rock Holding Corporation39DDenali Therapeutics Inc.52DViking Therapeutics, Inc.69BSELLAS Life Sciences Group, Inc.50DRest Ez Inc.——Kardigan, Inc.——Neighbors
Middlesex →Key facts
CEOJoshua Cohen
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: AMLX
Employees136
IPO date2022-01-07
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.